Multiple Options: How to Choose Therapy in Frontline Metastatic Melanoma

Purpose of Review Given the rapid development of multiple targeted and immune therapies for patients with advanced melanoma, it can be challenging to select a therapy based on currently available data. This review aims to provide an overview of frontline options for metastatic melanoma, with practic...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports 2024-08, Vol.26 (8), p.915-923
Main Authors: Kennedy, Lucy Boyce, Salama, April K. S.
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Clinical trials
Humans
Immune checkpoint inhibitors
Immune Checkpoint Inhibitors - therapeutic use
Immunotherapy
Immunotherapy - methods
Medicine
Medicine & Public Health
Melanoma
Melanoma - drug therapy
Melanoma - pathology
Metastases
Metastasis
Neoplasm Metastasis
Oncology
PD-1 protein
Proto-Oncogene Proteins B-raf - antagonists & inhibitors
Proto-Oncogene Proteins B-raf - genetics
Randomized Controlled Trials as Topic
Review
Skin Neoplasms - drug therapy
Skin Neoplasms - pathology
Topical Collection on Melanoma
Toxicity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review Given the rapid development of multiple targeted and immune therapies for patients with advanced melanoma, it can be challenging to select a therapy based on currently available data. This review aims to provide an overview of frontline options for metastatic melanoma, with practical guidance for selecting a treatment regimen. Recent Findings Recently reported data from randomized trials suggests that the majority of patients with unresectable melanoma should receive a PD-1 checkpoint inhibitor as part of their first line therapy, irrespective of BRAF mutation status. Additional data also suggests that combination immunotherapies result in improved outcomes compared to single agent, albeit at the cost of increased toxicity, though to date no biomarker exists to help guide treatment selection. Summary As the number therapeutic options continue to grow for patients with advanced melanoma, there is likely to be a continued focus on combination strategies. Defining the optimal treatment approach in order to maximize efficacy while minimizing toxicity remains an area of active investigation.
ISSN:1523-3790
1534-6269
1534-6269
DOI:10.1007/s11912-024-01547-0